Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

by · The Markets Daily

Maven Securities LTD purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 40,000 shares of the company’s stock, valued at approximately $3,551,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Squarepoint Ops LLC bought a new position in Spyre Therapeutics in the 2nd quarter valued at $12,394,000. Arizona State Retirement System increased its stake in shares of Spyre Therapeutics by 15.1% in the second quarter. Arizona State Retirement System now owns 15,471 shares of the company’s stock valued at $1,374,000 after buying an additional 2,033 shares in the last quarter. Nykredit A S acquired a new stake in shares of Spyre Therapeutics in the second quarter valued at $173,000. Allianz Asset Management GmbH bought a new position in shares of Spyre Therapeutics in the second quarter valued at about $1,252,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Spyre Therapeutics during the 2nd quarter worth about $999,000. 80.39% of the stock is owned by institutional investors and hedge funds.

Spyre Therapeutics Stock Performance

Shares of SYRE stock opened at $90.79 on Wednesday. The firm’s 50 day moving average price is $98.07 and its two-hundred day moving average price is $75.65. Spyre Therapeutics, Inc. has a 52-week low of $14.51 and a 52-week high of $110.18. The stock has a market cap of $7.98 billion, a PE ratio of -46.56 and a beta of 2.99.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.40. As a group, sell-side analysts predict that Spyre Therapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SYRE has been the subject of several research reports. Robert W. Baird set a $120.00 price objective on shares of Spyre Therapeutics in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Spyre Therapeutics from $135.00 to $127.00 and set a “buy” rating on the stock in a research report on Wednesday, August 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Spyre Therapeutics in a report on Tuesday, September 1st. BTIG Research reaffirmed a “buy” rating and set a $121.00 price objective on shares of Spyre Therapeutics in a report on Tuesday. Finally, Mizuho increased their price objective on Spyre Therapeutics from $84.00 to $120.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.69.

Check Out Our Latest Research Report on Spyre Therapeutics

Insider Activity

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $87.29, for a total value of $1,309,350.00. Following the sale, the chief executive officer directly owned 552,540 shares in the company, valued at approximately $48,231,216.60. This trade represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey W. Albers sold 18,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $104.55, for a total value of $1,881,900.00. Following the completion of the transaction, the director directly owned 9,360 shares of the company’s stock, valued at approximately $978,588. The trade was a 65.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 180,465 shares of company stock valued at $16,638,714. Insiders own 15.69% of the company’s stock.

Spyre Therapeutics Company Profile

(Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.

See Also

Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).